Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, PER

Servier Completes the Acquisition of Symphogen


PARIS, June 4, 2020 /CNW/ -- Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S.

Symphogen will now function as Servier's antibody center of excellence across multiple therapeutic areas, including oncology. Symphogen, now a Servier subsidiary, will keep its operational autonomy and continue to rely on its experienced employees while maintaining its headquarters in Ballerup, Denmark.

As part of the acquisition, Christophe Thurieau, Executive Director of Servier Research Institute, has been appointed Chief Executive Officer of Symphogen and Karin Garre, former Chief Operating Officer of Symphogen, has been appointed General Manager of Symphogen. Martin Olin, former Chief Executive Officer of Symphogen, will act as an external consultant to support this transition. 

Claude Bertrand, Executive Vice-President Research & Development at Servier, said: "The completion of this acquisition enables Servier to boost its antibody capabilities in oncology and its other therapeutic areas. The efficient antibody discovery and research platform of Symphogen will strengthen our R&D capabilities and pipeline in line with our aim of making life-saving treatments available to more patients across the world."

Christophe Thurieau, Executive Director of Servier Research Institute and Chief Executive Officer of Symphogen, added: "In line with the values of Symphogen, we also strongly believe that innovation and collaboration are key to develop treatments for the benefit of patients. We are very pleased to welcome Symphogen as part of the Servier Group and look forward to further collaborating with the team on developing breakthrough antibody therapies for patients."

Karin Garre, General Manager of Symphogen, concluded: "The completion of this transaction marks a very exciting journey for Symphogen and Servier. Anchored in a pre-existing strategic collaboration, this acquisition supports the R&D strategy of Servier within antibodies thanks to the capabilities of Symphogen. As the two organizations share key values, I believe this unification is positioned for a great outcome going forward." 

PDF: https://mma.prnewswire.com/media/1175338/Servier_PDF_EN.pdf  
Logo: https://mma.prnewswire.com/media/1175327/Servier_Logo.jpg

Contact:
Sonia Marques, [email protected], Tel. +33(0)1-55-72-40-21 / +33(0)7-84-28-76-13.
Jean-Clément Vergeau, [email protected], Tel. +33(0)1-55-72-46-16 / +33(0)6-79-56-75-96.

SOURCE Servier


These press releases may also interest you

at 16:15
Today Domo announced at Domopalooza: the AI + Data Conference a new wave of features for Domo.AI, the company's framework of flexible artificial intelligence (AI) services, powered by its award-winning platform. New features announced today help...

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...

at 16:15
  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell...

at 16:15
Yelp Inc. , the company that connects people with great local businesses, today announced the appointment of Dan Jedda, chief financial officer of Roku, Inc., to its Board of Directors, effective March 29, 2024. This appointment coincides with the...

at 16:15
Planet Labs PBC , a leading provider of daily data and insights about Earth, today announced it has signed a multi-year data-license agreement with Carbon Mapper, Inc. to provide hyperspectral core imagery to the non-profit and its partners until...

at 16:11
Qvest, a renowned leader in digital transformation across broadcast, media, and entertainment, will attend the NAB Show 2024. Hosted at booth W2821 in the Las Vegas Convention Center, the global company's participation is marked by a profound focus...



News published on and distributed by: